Bariatric surgery was associated with lower 2-year costs than GLP-1 therapy in adults with obesity and type 2 diabetes, according to new real-world data.
A claims-based analysis of nearly 91 000 adults with
“As GLP-1 use becomes more widespread, understanding their long-term financial impact compared with metabolic and bariatric surgery is increasingly important,” lead author Michael A. Edwards, MD, of Mayo Clinic in Jacksonville, Florida, said in a statement. He added that assumptions about lower upfront drug costs “don’t hold up when extended over time,” particularly when adherence, durability, and payer structure are considered.1
Key Facts
Investigators used the STATinMED RWD Insights all-payor claims database to evaluate patients treated from 2017 through 2023 who had body mass index of 35 or higher and type 2 diabetes. After propensity score matching, they compared 4931 patients receiving GLP-1 therapy with 4931 patients undergoing sleeve gastrectomy, and a separate matched cohort of 4272 GLP-1–treated patients with 4272 patients undergoing Roux-en-Y gastric bypass.1
Over 2 years, total costs were reported as $58,600 for GLP-1 treatment vs $41,400 for sleeve gastrectomy and $51,300 for gastric bypass. The investigators said these totals incorporated both treatment costs and costs related to persistent obesity-associated disease and complications, and that results varied by insurance type.1
The findings arrive as clinicians weigh the relative roles of surgery and pharmacotherapy for severe obesity complicated by diabetes. Current guidelines from the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders recommend metabolic and bariatric surgery for individuals with body mass index of 35 or higher regardless of obesity-related complications, and consideration beginning at body mass index 30 to 34.9 with metabolic disease.2 Separately, professional society guidance supports use of GLP-1–based medications, including semaglutide and tirzepatide, as effective options for chronic weight management in appropriate patients.3,4
Those treatment pathways differ in mechanism, durability, and practical barriers. Bariatric procedures such as sleeve gastrectomy and gastric bypass alter gastrointestinal anatomy and hormone signaling and can produce substantial, sustained weight loss with improvement in glycemia and other cardiometabolic end points.2 GLP-1 receptor agonists and related incretin therapies reduce appetite and improve glycemic control but generally require long-term continuation, and discontinuation is often followed by weight regain.3,4 For many patients, access to either approach is constrained by insurance coverage, out-of-pocket costs, and local availability of experienced multidisciplinary care.
The new analysis should be interpreted cautiously because it was presented at a scientific meeting and has not yet been published in a peer-reviewed journal. Important elements that would influence interpretation are still unclear, including the specific drugs evaluated, baseline disease severity after matching, medication adherence, crossover between treatment groups, and whether indirect costs or quality-of-life outcomes were assessed. The press release also noted that the study was conducted in collaboration with the Global Economics and Outcomes Research Group at Intuitive Surgical, which paid for database access.1
Even so, the report underscores a clinically relevant issue: cost comparisons based only on upfront procedural expense may not reflect longer-term spending in patients with severe obesity and type 2 diabetes. Whether these findings hold across specific GLP-1 or dual incretin agents, longer follow-up, and broader patient populations will likely require peer-reviewed publication and prospective comparative-effectiveness work.
